Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Hepatitis E: Are Rheumatic Patients at Risk?

CHRISTIAN H. ROUX, RODOLPHE ANTY, STEPHANIE PATOURAUX and LIANA EULLER-ZIEGLER
The Journal of Rheumatology January 2013, 40 (1) 99; DOI: https://doi.org/10.3899/jrheum.120599
CHRISTIAN H. ROUX
Service de Rhumatologie, Academic Hospital l’Archet 1, Nice;
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: roux101fr@yahoo.fr
RODOLPHE ANTY
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEPHANIE PATOURAUX
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LIANA EULLER-ZIEGLER
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

To the Editor:

Hepatitis E virus (HEV) is a major cause of acute hepatitis in developing countries, but remains infrequent in industrialized countries despite a growing number of cases1. It is a zoonosis related to domestic and also wild animals. In epidemic conditions HEV is transmitted mainly by drinking fecal-contaminated water, but it can also be transmitted person to person, or mother to fetus, and even through contaminated transfusions. Sporadic hepatitis E seems to be the most common manifestation in industrialized countries2. In France, genotype 3 is the most common. HEV infection is usually self-limited, symptomatic or asymptomatic, with possible acute hepatitis. Fulminant hepatitis may be observed in pregnant women and patients with underlying liver disease. Chronic infections can be detected in patients with transplants, lymphoma, leukemia with reactivation, in immunocompromised children, and in patients infected with human immunodeficiency virus.

We describe a patient with rheumatoid arthritis (RA), treated with rituximab (RTX) and methotrexate (MTX), who had liver enzyme elevations and HEV infection.

RA was diagnosed in 1993 in a man, then 40 years old, living in Corsica, with no notable medical history. Since 2008 he had been receiving a combination of weekly MTX 15 mg and RTX as 2 infusions: 1000 mg by intravenous (IV) infusion, followed by a second 1000 mg IV infusion 2 weeks later. The course was repeated every 6 months, with the last course in March 2011. At that time the alanine aminotransferase (ALT) level was 24 IU/l and aspartate aminotransferase (AST) was 25 IU/l. In June 2011, he was found to have anorexia, diarrhea, and abdominal pain and tenderness as well as painful hepatomegaly. He was given metronidazole 1 g/day between June 23 and July 8.

On hospital admission August 16, ALT level was 362 IU/l, AST 143 IU/l, γ-glutamyl transferase was 251 IU/l, alkaline phosphatase was 144 IU/l, and bilirubin was 13 μmol/l. HEV genotype 3 infection was diagnosed by reverse-transmission polymerase chain reaction, with HEV RNA in serum and stools, and concurrently with anti-HEV IgM in serum. A liver biopsy showed acute and chronic lesions, described during viral hepatitis E infection and eosinophilia, which could point to a possible drug-related cause. Fibrosis was classified as grade F0.

Ribavirin 400 mg twice a day was given for 3 months. On August 30 the ALT level was 1095 IU/l, AST was 679 IU/l, γ-glutamyl transferase was 251 IU/l, alkaline phosphatase was 144 IU/l, and bilirubin was 13 μmol/l.

The patient improved progressively and recovered fully within 3 months after onset. Liver function measures returned to normal limits: AST 26 IU/l, ALT 18 IU/l, and serum was clear of HEV RNA. RTX and MTX were reintroduced on November 29 without problems. No source for the HEV transmission including travel in endemic countries, drinking unsafe water, or eating undercooked pork could be identified.

The seroprevalence rate of IgG anti-HEV antibodies in France was 3.2% in blood donors in 20073, with large variations in different regions4. Because chronic immunosuppression is associated with increased viral replication and accelerated disease course, infections and viral reactivations may possibly arise in patients treated with RTX5,6,7. Cases of hepatitis E during treatment with RTX are rare or are not reported. To our knowledge only 1 case report of hepatitis E has been published8, in a patient with malignant non-Hodgkin’s lymphoma, and no case of hepatitis E has been reported in patients with RA.

The incubation period of HEV infection ranges from 2 to 6 weeks1. In our patient, according to the low severity of the case and the inverse relationship between severity of disease and incubation period, we can estimate that the period of contamination was probably in the second half of May 2011. In areas of low endemicity, clinical presentations can be icteric hepatitis, anicteric nonspecific illness, and often unexplained liver enzyme anomalies9.

As is often the case in sporadic appearance of disease, we were unable to confirm the source of transmission. A substantial body of data indicates that HEV infection is a porcine zoonosis, as pigs and wild boars are commonly infected. The source and route of autochthonous HEV infection are not clearly established, but recent recovery of HEV RNA genotype 3 in traditional pig liver sausages (figatelli) purchased in supermarkets, with statistically significant genetic links with sequences recovered from patients, strongly supports the hypothesis of HEV infection through ingestion of figatelli10. Our patient was living in Corsica, where consumption of figatelli is common and this kind of transmission is a possibility.

Although rare, the possibility of hepatitis E viral infection must be kept in mind in treated patients with RA when there is an unexplained increase in liver enzymes.

REFERENCES

  1. 1.↵
    1. Kamar N,
    2. Bendall R,
    3. Legrand-Abravanel F,
    4. Xia NS,
    5. Ijaz S,
    6. Izopet J,
    7. et al.
    Hepatitis E. Lancet 2012;379:2477–88.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Teshale EH,
    2. Hu DJ
    . Hepatitis E: Epidemiology and prevention. World J Hepatol 2011;3:285–91.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Boutrouille A,
    2. Bakkali-Kassimi L,
    3. Crucière C,
    4. Pavio N
    . Prevalence of anti-hepatitis E virus antibodies in French blood donors. J Clin Microbiol 2007;45:2009–10.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Renou C,
    2. Moreau X,
    3. Pariente A,
    4. Cadranel JF,
    5. Maringe E,
    6. Morin T,
    7. et al.
    A national survey of acute hepatitis E in France. Aliment Pharmacol Ther 2008;27:1086–93.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Rafailidis PI,
    2. Kakisi OK,
    3. Vardakas K,
    4. Falagas ME
    . Infectious complications of monoclonal antibodies used in cancer therapy: A systematic review of the evidence from randomized controlled trials. Cancer 2007;109:2182–9.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Spina M,
    2. Jaeger U,
    3. Sparano JA,
    4. Talamini R,
    5. Simonelli C,
    6. Michieli M,
    7. et al.
    Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV associated non-Hodgkin lymphoma: Pooled results from 3 phase 2 trials. Blood 2005;105:1891–7.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Aksoy S,
    2. Harputluoglu H,
    3. Kilickap S,
    4. Dede DS,
    5. Dizdar O,
    6. Altundag K,
    7. et al.
    Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007;48:1307–12.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Ollier L,
    2. Tieulie N,
    3. Sanderson F,
    4. Heudier P,
    5. Giordanengo V,
    6. Fuzibet JG
    . Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med 2009;150:430–1.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Mansuy JM,
    2. Peron JM,
    3. Abravanel Poirson H,
    4. Dubois M,
    5. Miedouge M,
    6. Vischi F,
    7. et al.
    Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol 2004;74:419–24.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Colson P,
    2. Borentain P,
    3. Queyriaux B,
    4. Kaba M,
    5. Moal V,
    6. Gallian P,
    7. et al.
    Pig liver sausage as a source of hepatitis E virus transmission to humans. J Infect Dis 2010;202:825–34.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 40, Issue 1
1 Jan 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hepatitis E: Are Rheumatic Patients at Risk?
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hepatitis E: Are Rheumatic Patients at Risk?
CHRISTIAN H. ROUX, RODOLPHE ANTY, STEPHANIE PATOURAUX, LIANA EULLER-ZIEGLER
The Journal of Rheumatology Jan 2013, 40 (1) 99; DOI: 10.3899/jrheum.120599

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Hepatitis E: Are Rheumatic Patients at Risk?
CHRISTIAN H. ROUX, RODOLPHE ANTY, STEPHANIE PATOURAUX, LIANA EULLER-ZIEGLER
The Journal of Rheumatology Jan 2013, 40 (1) 99; DOI: 10.3899/jrheum.120599
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Survival After Lung Transplantation in Patients With Rheumatoid Arthritis-Associated Lung Disease
  • Seasonal Variations and Their Influence on Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Relapse
  • Dr. Yoshida et al reply
Show more Letters

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire